Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Cash from Operations: 2018-2024

Historic Cash from Operations for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Dec 2024 value amounting to -$59.7 million.

  • Arcturus Therapeutics Holdings' Cash from Operations rose 27.83% to -$17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.3 million, marking a year-over-year increase of 2.94%. This contributed to the annual value of -$59.7 million for FY2024, which is 230.11% down from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Cash from Operations of -$59.7 million as of FY2024, which was down 230.11% from -$18.1 million recorded in FY2023.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Cash from Operations peaked at $32.0 million during FY2022, and registered a low of -$135.0 million during FY2021.
  • In the last 3 years, Arcturus Therapeutics Holdings' Cash from Operations had a median value of -$18.1 million in 2023 and averaged -$15.3 million.
  • In the last 5 years, Arcturus Therapeutics Holdings' Cash from Operations tumbled by 565.03% in 2020 and then spiked by 123.69% in 2022.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Cash from Operations (Yearly) stood at -$42.9 million in 2020, then crashed by 215.07% to -$135.0 million in 2021, then soared by 123.69% to $32.0 million in 2022, then plummeted by 156.57% to -$18.1 million in 2023, then crashed by 230.11% to -$59.7 million in 2024.